GlobeNewswire

ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors

Share

LYON, France, May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , is announcing that the Board of Directors will propose the appointment of Jean-Paul Kress as a Director at the Annual General Meeting on June 21, 2019, with a view to appointing him as Chairman of the Board of Directors. Dr. Kress possesses over 25 years’ experience as a senior executive in international biotech and pharma groups.

“I’m delighted that Jean-Paul Kress has agreed to join us to chair our Board of Directors. With our decision to split the duties of Chairman from those of Chief Executive Officer, we are taking concrete steps to enhance our governance strategy in preparation for the next stages in our Company’s development,” commented Gil Beyen, currently ERYTECH’s Chairman and Chief Executive Officer, who will stay on as Chief Executive Officer and a Director. “This represents a unique opportunity for us since Jean-Paul is well-known in the biopharmaceutical industry for his scientific and operational expertise, and for his international network of contacts, both of which will be highly beneficial for ERYTECH”.

Dr. Kress, M.D., was President and Chief Executive Officer and a member of the Board of Directors of Syntimmune from January 2018 until its acquisition by Alexion Pharmaceuticals in November 2018 for up to $1.2 billion. Prior to joining Syntimmune, Dr. Kress served as Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen Inc. Previously, Dr. Kress served as Senior Vice President, Head of North America at Sanofi Genzyme. From July 2011 to September 2015, Dr. Kress served as President and Chief Executive Officer of Sanofi Pasteur MSD, a leading European vaccine company. Prior to this, Dr. Kress worked at Gilead, Abbvie and Eli Lilly in senior commercial and business development roles in the United States and in Europe.

He was a member of Sarepta Therapeutics’ Board of Directors from 2015 until 2017.

Jean-Paul Kress holds an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees from École Normale Supérieure in Paris.

Dr. Kress commented: “I am excited to join ERYTECH at this stage of its development, not far from a expected commercial launch. ERYTECH stands out clearly among biotech companies with its unique high-potential technology, supported by a large volume of promising clinical data. I would like to thank Gil Beyen and ERYTECH’s Board of Directors and look forward to a productive collaboration.”

About ERYTECH: www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.

ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in preparations to enter Phase 2 clinical development for the treatment of triple-negative breast cancer. ERYTECH’s next product candidate erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers, has demonstrated promising preclinical results and is in preparations to enter Phase 1 clinical development.

ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies (ERYZYME).

ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility has recently completed construction in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS 

ERYTECH    
Eric Soyer
CFO & COO
NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations
   
+33 4 78 74 44 38
investors@erytech.com

+33 1 44 71 94 94
erytech@newcap.eu


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

MSAB: Continued investment for growth19.7.2019 08:00:00 CESTPress release

January - June Net sales increased 1.6 percent to SEK 130.4 (128.3) million (-4 percent in local currencies). EBIT amounted to SEK -17.1 (3.8) million. The EBIT margin was -13.1 (3.0) percent. Profit after tax amounted to SEK -15.3 (5.7) million. Earnings per share amounted to SEK -0.83 (0.31). Cash flow from operating activities amounted to SEK -6.2 (-11.1) million. Cash and cash equivalents and short-term investments amounted to SEK 52.5 (80.4) million at the end of the period. Second quarter Net sales increased 1.7 percent to SEK 64.1 (63.0) million (-4 percent in local currencies). EBIT amounted to SEK -11.4 (0.1) million. The EBIT margin was -17.8 (0.2) percent. Profit after tax amounted to SEK -10.8 (1.3) million. Earnings per share amounted to SEK -0.58 (0.07). Cash flow from operating activities amounted to SEK 0.7 (-11.4) million. Comments from the CEO Sales amounted to SEK 130.4 (128.3) million for the first six months of the year. EBIT came in at SEK -17.1 (3.8) million, the

MSAB: Fortsatta satsningar för tillväxt19.7.2019 08:00:00 CESTPressemelding

Januari - juni Nettoomsättningen ökade med 1,6 procent till 130,4 (128,3) mkr (-4 procent i lokala valutor) Rörelseresultatet uppgick till -17,1 (3,8) mkr Rörelsemarginalen uppgick till -13,1 (3,0) procent Resultat efter skatt uppgick till -15,3 (5,7) mkr Resultat per aktie uppgick till -0,83 (0,31) kr Kassaflöde från den löpande verksamheten uppgick till -6,2 (-11,1) mkr Likvida medel och kortfristiga placeringar uppgick vid periodens utgång till 52,5 (80,4) mkr Andra kvartalet Nettoomsättningen ökade med 1,7 procent till 64,1 (63,0) mkr, (-4 procent i lokala valutor) Rörelseresultatet uppgick till -11,4 (0,1) mkr Rörelsemarginalen uppgick till -17,8 (0,2) procent Resultat efter skatt uppgick till -10,8 (1,3) mkr Resultat per aktie uppgick till -0,58 (0,07) kr Kassaflöde från den löpande verksamheten uppgick till 0,7 (-11,4) mkr VDs kommentarer Omsättningen uppgick till 130,4 (128,3) mkr för årets första sex månader. Rörelseresultatet blev -17,1 (3,8) mkr, det försämrade resultatet är

Kinnevik:Interim Report 1 January - 30 June 201919.7.2019 08:00:00 CESTPress release

”It was an eventful second quarter, during which we focused our efforts on continuing the shift in our portfolio towards growth companies. These efforts included supporting high-performers in our private portfolio, evaluating our Millicom stake and supporting the IPO of Global Fashion Group.” Georgi Ganev, CEO of Kinnevik KEY PORTFOLIO DEVELOPMENTS Global Fashion Group began trading on the Frankfurt Stock Exchange on 2 July. The company raised a total of c. EUR 200m, of which EUR 60m from Kinnevik, to fuel continued growth Livongo announced its intention to go public at a proposed price range corresponding to a fully diluted pre-money valuation of USD 2.1-2.4bn. Kinnevik has agreed to purchase additional shares at the IPO price from one of Livongo’s investors, and we have also indicated our interest in purchasing newly issued shares in the IPO INVESTMENT MANAGEMENT ACTIVITIES Total investments of SEK 1,367m during the quarter, whereof SEK 632m in GFG, SEK 336m in Kolonial, SEK 156m in

Kinnevik:Delårsrapport 1 januari - 30 juni 201919.7.2019 08:00:00 CESTPressemelding

” Det har varit ett händelserikt andra kvartal, under vilket vi har fortsatt arbetet med att vikta om vår portfölj till en större andel tillväxtbolag. Detta har gjorts bland annat genom att stötta högpresterande bolag i vår privata portfölj, utvärdera vårt ägande i Millicom, samt genom att stötta börsnoteringen av Global Fashion Group. ” Georgi Ganev, Kinneviks vd VIKTIGA HÄNDELSER I PORTFÖLJEN Global Fashion Group började handlas på Frankfurtbörsen 2 juli. I samband med börsintroduktionen genomförde bolaget en nyemission om cirka 200 MEUR varav 60 MEUR från Kinnevik, i syfte att driva fortsatt tillväxt Livongo har meddelat att man avser börsnoteras med ett tilltänkt prisintervall som motsvarar en värdering på fullt utspädd basis om 2,1-2,4 MdUSD före emission av nya aktier i samband med börsnoteringen. Kinnevik har kommit överens om att köpa aktier från en av Livongos investerare till det slutliga priset i noteringen, och vi har även meddelat vårt intresse av att köpa ytterligare nyem

Huhtamäki Oyj’s Half-yearly Report January 1–June 30, 2019: Strong net sales growth and solid profitability19.7.2019 07:30:00 CESTPress release

HUHTAMÄKI OYJ HALF-YEARLY REPORT 19.7.2019 AT 8:30 Huhtamäki Oyj’s Half-yearly Report January 1–June 30, 2019: Strong net sales growth and solid profitability Q2 2019 in brief Net sales grew to EUR 867 million (EUR 786 million) Adjusted EBIT was EUR 78 million (EUR 71 million); reported EBIT EUR 78 million (EUR 80 million) Adjusted EPS was EUR 0.51 (EUR 0.46); reported EPS EUR 0.51 (EUR 0.54) Comparable net sales growth was 6% at Group level and 7% in emerging markets Currency movements had a positive impact of EUR 25 million on the Group’s net sales and EUR 2 million on EBIT H1 2019 in brief Net sales grew to EUR 1,669 million (EUR 1,511 million) Adjusted EBIT was EUR 146 million (EUR 131 million); reported EBIT EUR 145 million (EUR 141 million) Adjusted EPS was EUR 0.95 (EUR 0.86); reported EPS EUR 0.95 (EUR 0.93) Comparable net sales growth was 5% at Group level and 7% in emerging markets Currency movements had a positive impact of EUR 44 million on the Group’s net sales and EUR 4 m

Sinch AB (publ): Delårsrapport januari – juni 201919.7.2019 07:30:00 CESTPressemelding

Delårsrapport januari – juni 2019 April – juni 2019 Nettoomsättningen ökade med 18 procent till 1 176,7 MSEK (997,4). Den organiska tillväxten i lokal valuta var 15 procent. Bruttoresultatet ökade med 29 procent till 321,1 MSEK (248,6). Den organiska tillväxten i lokal valuta var 26 procent. Justerad EBITDA2 ökade med 17 procent till 114,2 MSEK (97,4). Justerad EBIT3 uppgick till 104,1 MSEK (91,2). Kvartalets resultat efter skatt uppgick till 53,3 MSEK (29,0). Resultat per aktie efter utspädning uppgick till 0,98 SEK (0,54). Januari – juni 2019 Nettoomsättningen ökade med 23 procent till 2 278,4 MSEK (1 856,0). Den organiska tillväxten i lokal valuta var 16 procent1. Bruttoresultatet ökade med 36 procent till 610,6 MSEK (448,6). Den organiska tillväxten i lokal valuta var 24 procent1. Justerad EBITDA2 ökade med 39 procent till 226,4 MSEK (162,3). Justerad EBIT3 uppgick till 206,3 MSEK (149,9). Periodens resultat efter skatt uppgick till 111,1 MSEK (38,3). Resultat per aktie efter utspä